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ABSTRACT
Background: Hereditary angioedema (HAE) is a rare but life-threatening condition that results from mutations
in C1-inhibitor (C1-INH). Since distinguishing HAE from other causes of angioedema (AE) is a critical problem
in emergencies, the objective of the present study was to clarify the differences between HAE and other forms
of AE.
Methods: Seventy-two patients with AE were enrolled in this study. The medical history and laboratory data of
patients with HAE at the first visit were compared to those with other types of AE.
Results: Subjects included 23 patients with HAE, 33 with mast cell-mediated AE, 5 with drug-induced AE and
11 with idiopathic AE. The average age of HAE onset (19.5 ± 8.0 years old) was significantly lower than in other
groups. A family history of AE was noted in 82.6% of HAE patients, which was significantly higher than other
groups. Swelling affecting the extremities and gastrointestinal (GI) tract was observed in the majority (60 to
80%) of HAE patients. Life threatening laryngeal edema was observed in 30.4% of HAE patients. In 95.6% of
HAE patients serum levels of C4 were less than the lower limit of the normal range. In our subjects, the sensi-
tivity and specificity of low C4 for HAE were 95.6% and 93.8%, respectively.
Conclusions: Early onset of AE, positive family history, recurrent AE in the extremities and GI tract, and suf-
focation are distinctive characteristics of HAE. A low serum level of C4 is a useful marker for making a differen-
tial diagnosis of HAE.
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INTRODUCTION
Angioedema (AE) is clinically characterized by self-
limiting attacks of marked edema involving the skin,
airway, gastrointestinal (GI) tract and other organs,1
and may or may not have a trigger event.2 Hereditary
angioedema (HAE) is an autosomal dominant disease
caused by an inherited deficiency of the functionally
active C1-inhibitor (C1-INH). Spontaneous new muta-
tions often occur, and are related to about 20% of HAE
cases.1,2 C1-INH belongs to the serpin family and
regulates the contact, complement and fibrinolysis
systems via its serine protease inhibitory effect. Ex-
cessive bradykinin formation due to the pathological
activation of the factor XII-driven plasma contact sys-
tem is a consistent finding in acute episodes of HAE.
Since plasma-derived C1-INH concentrate is available
for first-line treatment of acute HAE attacks, such as
life-threatening laryngeal edema and GI tract edema,
the discrimination of HAE from other causes of AE is
critical for effective treatment. However, correct diag-
nosis of HAE is, in some cases, made after a delay of
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approximately 20 years following the initial symp-
toms.3,4 Recently, we investigated the difficulties as-
sociated with initial diagnosis in cases of severe ab-
dominal attack with leukocytosis and high hematocrit
without CRP elevation, as such cases can be confused
with an acute abdomen, which can require an emer-
gency surgical procedure.4
According to the World Allergy Organization
(WAO) Guideline for the Management of HAE, HAE
patients can be screened for low serum levels of C4
and diagnosed by low functional and antigenic levels
of C1-INH.5 However, the measurement of functional
levels of C1-INH requires commercial testing that can
take up to 10 to 14 days and evaluation of antigenic
levels of C1-INH is not approved by the Japanese
health insurance system. Therefore, we undertook
this retrospective clinical study of various AE patients
with the aim of identifying useful characteristics that
can differentiate HAE from other types of AE.
METHODS
SUBJECTS
At the outpatient clinic of Juntendo University Hospi-
tal (Tokyo, Japan), 72 AE patients were enrolled from
February 2010 to August 2013. All patients had a con-
firmed AE occurrence from their own self-
photographs of the AE site andor had introduction
letters from their general physician. The HAE diagno-
sis criteria described by Agostoni, et al.6 were used in
this study. The major clinical criteria are: (1) self-
limiting, non-inflammatory subcutaneous angioedema
without major urticarial rash, often recurrent and
often lasting more than 12 hours, (2) self-remitting
abdominal pain without clear organic etiology, often
recurrent and often lasting more than 6 hours, and
(3) recurrent laryngeal edema. The minor clinical cri-
teria are: a family history of recurrent angioedema
andor abdominal pain andor laryngeal edema.
Laboratory criteria are: (1) C1 inhibitor antigenic lev-
els <50% of normal at two separate determinations
with the patient in a basal condition and after the first
year of age, (2) C1 inhibitor functional levels <50% of
normal at two separate determinations with the pa-
tient in a basal condition and after the first year of
age, and (3) a mutation in the C1 inhibitor gene alter-
ing protein synthesis andor function. Diagnosis of
HAE can be established with the presence of one ma-
jor (1-3) clinical criterion and one laboratory crite-
rion.
CATEGORY OF ANGIOEDEMA
All patients were divided into four groups: HAE, mast
cell-mediated AE with urticaria andor anaphylaxis
(mast-AE), drug-induced AE (d-AE), and idiopathic
AE (i-AE) according to the “International consensus
on hereditary angioedema and acquired angioe-
dema”.7 Additionally, 5 asymptomatic patients with a
C1-INH deficiency (as-HAE), who were relatives of
HAE patients, were also enrolled.
EVALUATION OF CLINICAL BACKGROUND AND
DATA
All historical locations of AE occurrences on the pa-
tient were recorded. Blood samples were obtained
from patients at the first consultation for a diagnosis
of AE to be made under normal conditions (no swel-
ling and no medication). The laboratory data for
white blood cells, eosinophils (Eo), red blood cells,
hemoglobin, hematocrit, serum creatinine (Cr), total
protein (TP), albumin (Alb), immunoglobulin (Ig) G,
IgM, IgA, and IgE, C3, C4, total hemolytic comple-
ment activity (CH50), C-reactive protein (CRP), fi-
brinogen and d-dimer were collected. For the pur-
pose of differential diagnosis, serum concentration of
immune complex (IC) [using a C1q-binding assay],
C1q and cryoglobulin were evaluated, and genetic
analysis of C1-INH was performed in some patients
with low functional levels of C1-INH and no family
history of AE. Functional levels of C1-INH were de-
termined using a chromogenic assay (Sysmex,
Hyogo, Japan). For differentiating collagen disease,
anti-nuclear antibody (ANA) in sera was also meas-
ured. The study was conducted in accordance with
the Declaration of Helsinki (1995) and was approved
by the Institutional Review Board at Juntendo Univer-
sity. Written informed consent was obtained from all
participating patients.
STATISTICAL ANALYSIS
GraphPad Prism 5 software for Windows (version
5.04; GraphPad, San Diego, CA, USA) was used for
statistical analysis and a two-sided p-value < 0.05 was
taken as the level for statistical significance. The rela-
tionship between categorical variables was analyzed
using a χ2 test. In the comparisons between grouped
items, one-factor analysis of variance (ANOVA), fol-
lowed by pair-wise comparisons with Bonferroni’s
correction was used when total ANOVA indicated a
significant difference. All data were expressed as
mean ± standard deviation (SD). Percentages shown
in Table 1-4 are rounded down to one decimal place.
RESULTS
SUBJECTS’ BACKGROUND
Subjects in this study included 23 HAE patients, 33
mast-AE patients (including 2 cases of IgE-mediated
anaphylaxis), 5 d-AE patients, 11 i-AE patients and 5
as-HAE patients (Table 1). The occurrences of d-AE
were due to enalapril, loxoprofen, an estrogen-
containing contraceptive drug, and candesartan; two
Chinese traditional herbs (Shakuyaku-Kanzo-To and
Boiogi-to) were suspected of causing d-AE. There
were no patients with acquired angioedema due to a
C1-INH deficiency or normal C1-INH with positive in-
heritance. Age at the first visit in the d-AE group was
high but there were no statistical differences between
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Allergology International Vol 63, No4, 2014 www.jsaweb.jp 597
Fig.　1　Distribution of age of onset and serum parameters. A: The age of the fi rst symp-
toms of angioedema (ANOVA: p < 0.0001, *Bonferroni’s analysis: p < 0.05). B: Antigenic 
serum levels of C4. C: functional levels of C1-inhibitor. The horizontal broken line repre-
sents the limit of quantitation. D: Antigenic levels of d-dimer. The horizontal line repre-
sents the upper limit of normal range. Abbreviations: HAE, hereditary angioedema; mast-
AE, mast cell-mediated angioedema with urticaria and/or anaphylaxis; d-AE, drug-induced 
angioedema; i-AE, idiopathic angioedema; as-HAE, asymptomatic relatives of HAE.
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Table　1　Characteristics of patients in the study
n Age of fi rst visit (years) M : F
Age of AE onset
(years)
Family history of AE
(% with history)
HAE 23 42.3 ± 14.3 10 : 13 19.5 ± 8.0† 82.6‡
mast-AE 33 41.2 ± 13.6  8 : 25 34.3 ± 14.0 9.0
d-AE  5 57.0 ± 21.0 1 : 4 55.0 ± 21.1 0.0
i-AE 11 47.2 ± 20.5 5 : 6 41.4 ± 26.6 9.0
as-AE  5 34.4 ± 17.5 3 : 2 - 100.0
†Signifi cantly lower than other groups (ANOVA: p < 0.0001, Bonferroni’s analysis: p < 0.05).
‡Signifi cantly higher than that of mast-AE, d-AE and i-AE groups (χ2 test: p < 0.0001).
Data presented above describe the number, mean (±SD) age at onset and fi rst visit, the percentage of patients with a family history, and 
the gender ratio of the patients in the study, divided into groups according to the etiology of their condition.
Abbreviations: AE, angioedema; HAE, hereditary AE; mast-AE, mast cell mediated AE with urticaria and/or anaphylaxis; d-AE, drug in-
duced AE; i-AE, idiopathic AE; as-AE, asymptomatic C1-inhibitor defi ciency.
any groups. However, the age of AE onset in the HAE
group (19.5 ± 8.0 years) was significantly lower than
that of the mast-AE, d-AE and i-AE groups (Fig. 1A).
A family history of AE was noted in 19 of the 23 HAE
patients (82.6%), which was a significantly higher rate
than that of the mast-AE, d-AE and i-AE groups (χ2
test: p < 0.0001). Four AE cases with low functional
levels of C1-INH, low concentration of C4 and having
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no family history of AE were diagnosed with HAE
with additional findings (Table 2). Patient number
(no.) 18, (a 54-year old female) had no positive re-
sults in evaluations of immunecomplex (IC), cryo-
globulin (Cryo), ANA, anti-double stranded DNA anti-
body (anti-dsDNA ab) and C1q. Patient no.28, (a 35-
year old female) presented with high concentration of
IC, but hetero-deletion of exon4 of C1-INH gene was
demonstrated (genetic analysis was performed by
Professor Takahiko Horiuchi, Internal Medicine, Ky-
usyu University Beppu Hospital, Oita, Japan). She did
not present with any symptoms commonly associated
with autoimmune disease andor infectious disease.
The remaining two cases visited our hospital seeking
a second opinion. Patient no. 53, (a 42-year old fe-
male) presented with repeated severe AE attacks of
her face and larynx from the age of 6 and has been
treated with C1-INH concentrate three times on de-
mand at a local hospital. Her blood examination
showed no positive results for evaluation of IC, Cryo,
ANA and anti-dsDNA ab. We could not evaluate the
concentration of C1q due to the patient having emi-
grated. Patient no.64, (a 32-year old male) had experi-
enced abdominal attacks since the age of 12, and had
previously been treated with C1-INH concentrate on
demand in another hospital. His blood examination
showed no positive findings; however, C1q concentra-
tion could not be measured. There was only one case
of i-AE (a 26-year old female) whose mother occasion-
ally experiences AE attacks on her eye lids, from age
5, and abdomen, from age 24. She showed no efficacy
with H1-blockade and corticosteroids. There was also
no diagnostic evidence in her blood examination.
There were no differences in the laboratory data,
such as blood cell counts, Eo, TP, Alb, Cr, CRP and
IgE, between AE groups (data not shown).
ANGIOEDEMA LOCATION
Facial edema, including lips, were common in all
groups of AE (Table 3). Extremities and GI tract AE
were noted in the majority (60 to 80%) of HAE pa-
tients, in comparison to other AE types (10 to 20%).
Tongue andor oral cavity AE were remarkable
symptoms present in 80% of patients with d-AE. La-
ryngeal edema was most frequently observed in the
HAE group (39.1%) compared to mast-AE (18.1%), d-
AE (20%) and i-AE (18.1%). Suffocation (subjects had
undergone airway management) was observed in
30.4% of HAE patients and 2 of them had undergone
tracheotomy. Genital AE was observed in HAE and i-
AE patients but not mast-AE and d-AE patients.
Amongst our subjects, there were no patients who
had undergone abdominal surgery due to abdominal
pain.
EVALUATION OF BIOMARKERS
Except for one as-HAE patient whose serum C3 level
was slightly below normal (67 mgdL), serum C3 lev-
Characteristics That Differentiate HAE
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. els in all patients were within the normal range (Ta-
ble 4). In 22 of 23 patients with HAE (95.6%) the se-
rum C4 levels were below the lower limit of the nor-
mal range (14 mgdL) and 4 HAE patients (17.3%)
presented extremely low levels of C4 below the limit
of quantitation (LOQ, <2 mgdL) (Fig. 1B). In 2 of 5
patients with as-HAE (40%) serum C4 levels were less
than the lower limit of the normal range. In 2 of 33 pa-
tients with mast-AE (6.0%) and 1 of 5 patients with d-
AE serum C4 levels were low (12, 13 and 10 mgdL
respectively). Patients with low CH50 levels were lim-
ited to the HAE and as-HAE groups. A total of 11 of
23 patients with HAE (47.8%) and 1 of 5 patients with
as-HAE (20%) presented CH50 levels below the lower
limit of the normal range (25 UmL). Levels of CH50
were lower than the LOQ (<7 UmL) in 2 of 23 pa-
tients with HAE (8.6%) but none of the as-HAE pa-
tients had serum CH50 levels that were extremely
low. A functional level of C1-INH less than 50% of nor-
mal was the diagnostic criterion used to diagnose
HAE, and patients with HAE and as-HAE fulfilled that
criterion (Fig. 1C). Furthermore, 14 of 23 (60.8%) pa-
tients with HAE presented functional levels of C1-
INH below the LOQ (<25%).
DIFFERENTIATION OF SUBJECTS
Figure 2 shows the differentiation of all subjects. The
results show that low C4 levels have a high sensitivity
and specificity for the diagnosis of HAE (95.6% and
93.8%, respectively) irrespective of whether the pa-
tients have a family history of AE. Of the four excep-
tions, the first was a 17-year old female who had a
family history of AE and low C4 (13 mgdL), but who
was not diagnosed with HAE (labeled ‘a’ in Fig. 2).
Since she had multi-drug allergy, and H1-blockade
was successful at treating swelling on her facial re-
gion and legs, she was diagnosed as having mast-AE.
The second was an HAE patient who had a positive
family history of AE and who was within the lower
limit of serum levels of C4 (14 mgdL), but whose
low serum C4 concentration (7 mgdL) was obtained
during an attack (‘b’ in Fig. 2). The third was a 19-
year old male who had no family history of AE but
had low C4 (12 mgdL), and was diagnosed with
mast-AE because lip and GI tract AE occurred after
urticaria. His symptoms responded well to H1-
blockade treatment (‘c’ in Fig. 2). Finally, a 46-year
old female, who had no family history of AE but had
low C4 (10 mgdL), was diagnosed with d-AE be-
cause her facial AE attacks disappeared after discon-
tinuation of loxoprofen (‘d’ in Fig. 2).
Serum concentration of fibrinogen was distributed
within a normal range and showed no statistical dif-
ference between each group (data not shown). In
contrast to fibrinogen, 16 cases of HAE (69.5%), 19 of
mast-AE (57.5%), 3 of d-AE (60%), 3 of i-AE (27.2%)
and 4 of as-AE (40%) presented a higher concentra-
tion of d-dimer than the normal range of <1 μgmL
Ohsawa I et al.
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(Fig. 1D).
DISCUSSION
Early diagnosis and treatment is key in patients with
HAE although the low awareness of HAE amongst
medical staff in Japan is a serious problem.8 Recent
national reports have suggested a similarity between
Japanese HAE patients and patients in other coun-
tries, in terms of a slight female predominance, age of
onset, percentage of sporadic cases, and frequencies
of abdominal and respiratory symptoms.3,4 However,
the many classifications of AE, defined from clinical
symptoms and pathophysiological viewpoints, have
led physicians to confuse the differential diagnosis of
AE.5,7 Thus, the predominance of HAE in all types of
AE has been not clarified. A Japanese national survey
indicated the prevalence of HAE was 13% among 41
patients of AE.9 Our observations in this retrospective
study have highlighted characteristics that may aid
physicians in correctly diagnosing HAE in patients
during the first contact.
Evaluating the past histories, age of onset and loca-
tion of AE in patients is very informative. The mean
age of onset in the HAE group was significantly lower
than that in other groups with a range of 4 to 39
years. However, some patients with a young age of
onset were observed in mast-AE and i-AE, and there-
fore the age of onset of AE was not a decisive indica-
tor for differential diagnosis of HAE. In patients with
HAE, 82.6% had a positive family history of AE and
the remaining cases of HAE would involve de novo
mutation. Previous western studies have also esti-
mated that HAE patients with autosomal dominant
trait account for 75 to 80% and de novo mutations ac-
count for at least 20 to 25% of all HAE patients.1,2,5,10
In order to confirm a diagnosis of HAE, patients with
acquired AE have to be excluded. Although the Japa-
nese health insurance system does not cover evalu-
ation of the antigenic level of C1-INH and C1q, we
performed further blood examination for differential
diagnosis of acquired AE using research budget. Al-
though patient no.28 had a confirmed genetic abnor-
mality of C1-INH, she presented with high serum
concentration of IC. Looking forward, we have to be
aware of the signs of autoimmune disease which are
often associated with HAE.11 Both patients no.53 and
64 had a history of early onset of AE. Although we
could not evaluate the concentration of C1q, they pre-
sented no other positive findings of acquired AE and
activators of the classical pathway. Because new on-
set of acquired AE after the age of 4012 and positivity
of low concentration of C1q for acquired AE have
been reported 70%,13 we provisionally diagnosed
them with HAE.
All types of AE share facial AE, the so-called
“Quincke’s edema”. By contrast, extremities and
genital AE were observed in over 65% and 20% of pa-
tients with HAE, respectively, therefore attention
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Fig.　2　Differentiation of subjects. With the possible exception of acquired AE, low C4 is a distinc-
tive characteristic for differentiating HAE. Details of each patient (a, b, c, d) refer to results in the 
text.
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should be paid to swelling in these areas of a patient’s
body. Oral cavity and laryngeal AE were observed in
all groups of AE but suffocation was observed in HAE
and mast-AE. Thus, a history of tracheotomy is an im-
portant indicator for the diagnosis of HAE. As ab-
dominal attacks were observed in over 60% of patients
with HAE, repeated abdominal attacks and any ad-
missions for abdominal pain might become diagnos-
tic hallmarks. In a patient survey among 209 German
HAE patients, the frequencies of AE in the extremi-
ties, genitalia and larynx were 93.8%, 62.7% and 54%
respectively.2 Although the frequency in our subjects
was less than this report, we can state that the loca-
tion of AE in Japanese and German patients shows
the same tendency.
As the results of serum C4 concentration tests can
be obtained within several hours to a day, the World
Allergy Organization (WAO) guideline recommends
C4 as the single best screening test, and repeating C4
tests during an attack increases the probability that a
low C4 concentration will be found.5 In our results,
the low serum levels of C4 showed a high level of
sensitivity (95.6%) and specificity (93.8%) for HAE. In
only one case of HAE were C4 levels slightly higher
than the lower limit of the normal level of C4, but
even in this case, the second measurement showed a
low C4 concentration during an attack. Although the
WAO did not include Japanese data, the measure-
ment of serum C4 levels may be useful for screening
HAE in Japanese patients. Low titers of CH50 were
only observed in HAE (47.8%) and as-HAE patients
(20%), and 8.6% with patients of HAE presented a
CH50 titer value below LOQ. Since as-HAE presented
a low prevalence of low serum C4 levels, complement
classical and lectin pathways might be relatively well
controlled regardless of the low functional levels of
C1-INH. In the context of differentiating between
types of AE, we have to first check for acquired AE by
observing a patient’s symptoms and laboratory find-
ings. However, as it is difficult to discriminate HAE
from mast-AE, low serum C4 levels are a useful indi-
cator of HAE that can be tested quickly ahead of the
results of C1-INH activity.
C1-INH has several inhibitory activities as a “ser-
pin”; it inhibits not only the contact system but also
the complement and fibrinolytic systems. Since d-
dimer is a fibrin degradation product, HAE patients in
remission often present with a high serum level of d-
dimer, and during attacks, HAE patients present with
a further elevation of d-dimer.14,15 In our results, HAE
and mast-AE patients presented relatively higher se-
rum levels of d-dimer than patients with other types
of AE, but there were a few cases with high serum d-
dimer levels in d-AE or i-AE groups. Previous reports
have indicated that a high serum d-dimer concentra-
tion may be present in patients with chronic urti-
caria,12,16 indicating that there are common mecha-
nisms that lead to elevated serum d-dimer concentra-
tions. The measurement of d-dimer therefore was not
a decisive differentiator for HAE.
In conclusion, this study underlines the importance
of clinical characteristics of HAE for diagnosis, such
as the early onset of AE, a family history of AE, and
recurrent AE located in the extremities, genitals and
GI tract. In laboratory findings, a low serum C4 level
is an excellent marker for the differential diagnosis of
HAE over other types of AE.
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